ES2642633T3 - Prevención y/o tratamiento de la enfermedad cardiovascular y/o la insuficiencia cardíaca asociada - Google Patents

Prevención y/o tratamiento de la enfermedad cardiovascular y/o la insuficiencia cardíaca asociada Download PDF

Info

Publication number: ES2642633T3
Authority: ES; Spain
Prior art keywords: diabetic; agent; copper; arteries; trientine
Prior art date: 2002-03-08
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

ES11187394.9T

Other languages

English (en)

Spanish (es)

Inventor

Garth James Smith Cooper

John Richard Baker

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

PHILERA NEW ZEALAND Ltd

Original Assignee

PHILERA NEW ZEALAND Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-03-08

Filing date

2003-03-10

Publication date

2017-11-17

2003-03-10 Application filed by PHILERA NEW ZEALAND Ltd filed Critical PHILERA NEW ZEALAND Ltd

2017-11-17 Application granted granted Critical

2017-11-17 Publication of ES2642633T3 publication Critical patent/ES2642633T3/es

2023-03-10 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

206010019280 Heart failures Diseases 0.000 title claims description 13
230000002265 prevention Effects 0.000 title description 4
208000024172 Cardiovascular disease Diseases 0.000 title description 2
206010012601 diabetes mellitus Diseases 0.000 claims description 207
239000010949 copper Substances 0.000 claims description 106
229910052802 copper Inorganic materials 0.000 claims description 97
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 85
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 77
VILCJCGEZXAXTO-UHFFFAOYSA-N 2,2,2-tetramine Chemical compound NCCNCCNCCN VILCJCGEZXAXTO-UHFFFAOYSA-N 0.000 claims description 73
229960001124 trientine Drugs 0.000 claims description 69
210000002216 heart Anatomy 0.000 claims description 63
229910052742 iron Inorganic materials 0.000 claims description 40
239000003814 drug Substances 0.000 claims description 38
229940079593 drug Drugs 0.000 claims description 36
239000003795 chemical substances by application Substances 0.000 claims description 27
238000000034 method Methods 0.000 claims description 25
230000000747 cardiac effect Effects 0.000 claims description 20
210000000056 organ Anatomy 0.000 claims description 18
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 17
210000004204 blood vessel Anatomy 0.000 claims description 13
208000031229 Cardiomyopathies Diseases 0.000 claims description 12
230000006378 damage Effects 0.000 claims description 12
230000017423 tissue regeneration Effects 0.000 claims description 12
230000002792 vascular Effects 0.000 claims description 12
230000001419 dependent effect Effects 0.000 claims description 11
239000002738 chelating agent Substances 0.000 claims description 10
230000003902 lesion Effects 0.000 claims description 10
WYHIICXRPHEJKI-UHFFFAOYSA-N Trientine hydrochloride Chemical compound Cl.Cl.NCCNCCNCCN WYHIICXRPHEJKI-UHFFFAOYSA-N 0.000 claims description 8
229960002408 trientine hydrochloride Drugs 0.000 claims description 8
230000002526 effect on cardiovascular system Effects 0.000 claims description 7
210000003734 kidney Anatomy 0.000 claims description 7
210000002565 arteriole Anatomy 0.000 claims description 6
231100000331 toxic Toxicity 0.000 claims description 6
230000002588 toxic effect Effects 0.000 claims description 6
210000000709 aorta Anatomy 0.000 claims description 5
210000004351 coronary vessel Anatomy 0.000 claims description 5
210000001105 femoral artery Anatomy 0.000 claims description 5
210000004165 myocardium Anatomy 0.000 claims description 5
AGGKEGLBGGJEBZ-UHFFFAOYSA-N tetramethylenedisulfotetramine Chemical compound C1N(S2(=O)=O)CN3S(=O)(=O)N1CN2C3 AGGKEGLBGGJEBZ-UHFFFAOYSA-N 0.000 claims description 5
208000002972 Hepatolenticular Degeneration Diseases 0.000 claims description 4
208000018839 Wilson disease Diseases 0.000 claims description 4
210000001367 artery Anatomy 0.000 claims description 4
210000001715 carotid artery Anatomy 0.000 claims description 4
210000003090 iliac artery Anatomy 0.000 claims description 4
OKHMDSCYUWAQPT-UHFFFAOYSA-N n'-[2-(2-aminoethylamino)ethyl]ethane-1,2-diamine;tetrahydrochloride Chemical compound Cl.Cl.Cl.Cl.NCCNCCNCCN OKHMDSCYUWAQPT-UHFFFAOYSA-N 0.000 claims description 4
210000003137 popliteal artery Anatomy 0.000 claims description 4
210000002254 renal artery Anatomy 0.000 claims description 4
UWMHHZFHBCYGCV-UHFFFAOYSA-N 2,3,2-tetramine Chemical compound NCCNCCCNCCN UWMHHZFHBCYGCV-UHFFFAOYSA-N 0.000 claims description 3
208000030159 metabolic disease Diseases 0.000 claims description 3
210000005036 nerve Anatomy 0.000 claims description 3
210000001525 retina Anatomy 0.000 claims description 3
208000025494 Aortic disease Diseases 0.000 claims description 2
230000001413 cellular effect Effects 0.000 claims description 2
238000009509 drug development Methods 0.000 claims description 2
210000001508 eye Anatomy 0.000 claims description 2
230000001434 glomerular Effects 0.000 claims description 2
230000007170 pathology Effects 0.000 claims description 2
230000035479 physiological effects, processes and functions Effects 0.000 claims description 2
230000002207 retinal effect Effects 0.000 claims description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
210000003169 central nervous system Anatomy 0.000 claims 1
210000001428 peripheral nervous system Anatomy 0.000 claims 1
241001465754 Metazoa Species 0.000 description 119
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 86
ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 44
210000001519 tissue Anatomy 0.000 description 44
239000011780 sodium chloride Substances 0.000 description 43
230000028327 secretion Effects 0.000 description 39
230000037396 body weight Effects 0.000 description 35
210000002700 urine Anatomy 0.000 description 34
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 30
210000000130 stem cell Anatomy 0.000 description 27
229910001868 water Inorganic materials 0.000 description 26
230000036586 afterload Effects 0.000 description 25
241000700159 Rattus Species 0.000 description 23
230000000694 effects Effects 0.000 description 21
238000002474 experimental method Methods 0.000 description 21
210000004369 blood Anatomy 0.000 description 19
239000008280 blood Substances 0.000 description 19
230000002861 ventricular Effects 0.000 description 18
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 17
230000004075 alteration Effects 0.000 description 17
239000008103 glucose Substances 0.000 description 17
230000004044 response Effects 0.000 description 17
238000004458 analytical method Methods 0.000 description 16
230000036316 preload Effects 0.000 description 15
230000008929 regeneration Effects 0.000 description 14
238000011069 regeneration method Methods 0.000 description 14
210000002966 serum Anatomy 0.000 description 14
230000002485 urinary effect Effects 0.000 description 13
239000000523 sample Substances 0.000 description 12
208000027418 Wounds and injury Diseases 0.000 description 11
238000010586 diagram Methods 0.000 description 11
230000004217 heart function Effects 0.000 description 11
208000014674 injury Diseases 0.000 description 11
230000001404 mediated effect Effects 0.000 description 10
238000009825 accumulation Methods 0.000 description 9
239000000872 buffer Substances 0.000 description 9
230000036755 cellular response Effects 0.000 description 9
230000006872 improvement Effects 0.000 description 9
230000007246 mechanism Effects 0.000 description 9
230000009467 reduction Effects 0.000 description 9
238000012360 testing method Methods 0.000 description 9
229910052723 transition metal Inorganic materials 0.000 description 9
239000004698 Polyethylene Substances 0.000 description 8
201000010099 disease Diseases 0.000 description 8
230000006870 function Effects 0.000 description 8
210000005003 heart tissue Anatomy 0.000 description 8
238000001990 intravenous administration Methods 0.000 description 8
230000008439 repair process Effects 0.000 description 8
238000001356 surgical procedure Methods 0.000 description 8
150000003624 transition metals Chemical class 0.000 description 8
230000008030 elimination Effects 0.000 description 7
238000003379 elimination reaction Methods 0.000 description 7
238000002347 injection Methods 0.000 description 7
239000007924 injection Substances 0.000 description 7
230000005012 migration Effects 0.000 description 7
238000013508 migration Methods 0.000 description 7
238000002560 therapeutic procedure Methods 0.000 description 7
210000004027 cell Anatomy 0.000 description 6
238000011161 development Methods 0.000 description 6
230000018109 developmental process Effects 0.000 description 6
238000011049 filling Methods 0.000 description 6
238000005259 measurement Methods 0.000 description 6
229910052751 metal Inorganic materials 0.000 description 6
239000002184 metal Substances 0.000 description 6
230000010412 perfusion Effects 0.000 description 6
150000003254 radicals Chemical class 0.000 description 6
239000000243 solution Substances 0.000 description 6
208000037816 tissue injury Diseases 0.000 description 6
206010054805 Macroangiopathy Diseases 0.000 description 5
241000124008 Mammalia Species 0.000 description 5
ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 5
230000008859 change Effects 0.000 description 5
208000035475 disorder Diseases 0.000 description 5
238000000673 graphite furnace atomic absorption spectrometry Methods 0.000 description 5
BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 5
229960003132 halothane Drugs 0.000 description 5
238000001802 infusion Methods 0.000 description 5
230000003993 interaction Effects 0.000 description 5
229960001052 streptozocin Drugs 0.000 description 5
229910021654 trace metal Inorganic materials 0.000 description 5
210000003462 vein Anatomy 0.000 description 5
239000011701 zinc Substances 0.000 description 5
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
241000700157 Rattus norvegicus Species 0.000 description 4
208000025865 Ulcer Diseases 0.000 description 4
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
230000001746 atrial effect Effects 0.000 description 4
230000008901 benefit Effects 0.000 description 4
230000008602 contraction Effects 0.000 description 4
-1 copper Chemical class 0.000 description 4
230000006698 induction Effects 0.000 description 4
230000002107 myocardial effect Effects 0.000 description 4
239000001301 oxygen Substances 0.000 description 4
229910052760 oxygen Inorganic materials 0.000 description 4
230000008569 process Effects 0.000 description 4
230000001629 suppression Effects 0.000 description 4
230000004083 survival effect Effects 0.000 description 4
229910052725 zinc Inorganic materials 0.000 description 4
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 3
238000010521 absorption reaction Methods 0.000 description 3
230000002411 adverse Effects 0.000 description 3
238000000540 analysis of variance Methods 0.000 description 3
230000036760 body temperature Effects 0.000 description 3
239000008367 deionised water Substances 0.000 description 3
229910021641 deionized water Inorganic materials 0.000 description 3
235000005911 diet Nutrition 0.000 description 3
230000037213 diet Effects 0.000 description 3
239000003651 drinking water Substances 0.000 description 3
235000020188 drinking water Nutrition 0.000 description 3
239000007789 gas Substances 0.000 description 3
229910002804 graphite Inorganic materials 0.000 description 3
239000010439 graphite Substances 0.000 description 3
230000035876 healing Effects 0.000 description 3
208000015181 infectious disease Diseases 0.000 description 3
239000000463 material Substances 0.000 description 3
150000002739 metals Chemical class 0.000 description 3
208000010125 myocardial infarction Diseases 0.000 description 3
229910017604 nitric acid Inorganic materials 0.000 description 3
238000007619 statistical method Methods 0.000 description 3
230000036269 ulceration Effects 0.000 description 3
206010002091 Anaesthesia Diseases 0.000 description 2
241000283690 Bos taurus Species 0.000 description 2
108010075016 Ceruloplasmin Proteins 0.000 description 2
102100023321 Ceruloplasmin Human genes 0.000 description 2
208000002705 Glucose Intolerance Diseases 0.000 description 2
206010018429 Glucose tolerance impaired Diseases 0.000 description 2
241000282412 Homo Species 0.000 description 2
206010020772 Hypertension Diseases 0.000 description 2
239000008002 Krebs-Henseleit bicarbonate buffer Substances 0.000 description 2
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
208000028389 Nerve injury Diseases 0.000 description 2
108090000854 Oxidoreductases Proteins 0.000 description 2
102000004316 Oxidoreductases Human genes 0.000 description 2
208000004880 Polyuria Diseases 0.000 description 2
208000001647 Renal Insufficiency Diseases 0.000 description 2
206010061481 Renal injury Diseases 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
239000002250 absorbent Substances 0.000 description 2
230000002745 absorbent Effects 0.000 description 2
230000001154 acute effect Effects 0.000 description 2
230000037005 anaesthesia Effects 0.000 description 2
238000013459 approach Methods 0.000 description 2
229910052786 argon Inorganic materials 0.000 description 2
230000004791 biological behavior Effects 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
230000036772 blood pressure Effects 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
238000012937 correction Methods 0.000 description 2
230000004069 differentiation Effects 0.000 description 2
230000029087 digestion Effects 0.000 description 2
231100000673 dose–response relationship Toxicity 0.000 description 2
238000002651 drug therapy Methods 0.000 description 2
230000003511 endothelial effect Effects 0.000 description 2
230000002169 extracardiac Effects 0.000 description 2
235000012631 food intake Nutrition 0.000 description 2
238000009472 formulation Methods 0.000 description 2
210000002064 heart cell Anatomy 0.000 description 2
230000002706 hydrostatic effect Effects 0.000 description 2
201000001421 hyperglycemia Diseases 0.000 description 2
230000001631 hypertensive effect Effects 0.000 description 2
230000001771 impaired effect Effects 0.000 description 2
201000006370 kidney failure Diseases 0.000 description 2
210000005246 left atrium Anatomy 0.000 description 2
210000005240 left ventricle Anatomy 0.000 description 2
210000004185 liver Anatomy 0.000 description 2
238000012423 maintenance Methods 0.000 description 2
239000000203 mixture Substances 0.000 description 2
238000012544 monitoring process Methods 0.000 description 2
230000008764 nerve damage Effects 0.000 description 2
239000008188 pellet Substances 0.000 description 2
206010036067 polydipsia Diseases 0.000 description 2
229920000573 polyethylene Polymers 0.000 description 2
238000002203 pretreatment Methods 0.000 description 2
238000005070 sampling Methods 0.000 description 2
208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
210000005167 vascular cell Anatomy 0.000 description 2
230000003442 weekly effect Effects 0.000 description 2
238000012935 Averaging Methods 0.000 description 1
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
206010010957 Copper deficiency Diseases 0.000 description 1
JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 description 1
YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
208000007342 Diabetic Nephropathies Diseases 0.000 description 1
208000032781 Diabetic cardiomyopathy Diseases 0.000 description 1
102000008857 Ferritin Human genes 0.000 description 1
108050000784 Ferritin Proteins 0.000 description 1
238000008416 Ferritin Methods 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
239000007836 KH2PO4 Substances 0.000 description 1
102000003820 Lipoxygenases Human genes 0.000 description 1
108090000128 Lipoxygenases Proteins 0.000 description 1
PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
239000012901 Milli-Q water Substances 0.000 description 1
206010067482 No adverse event Diseases 0.000 description 1
239000004793 Polystyrene Substances 0.000 description 1
206010063493 Premature ageing Diseases 0.000 description 1
208000032038 Premature aging Diseases 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
238000000692 Student's t-test Methods 0.000 description 1
102000019197 Superoxide Dismutase Human genes 0.000 description 1
108010012715 Superoxide dismutase Proteins 0.000 description 1
RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
238000010162 Tukey test Methods 0.000 description 1
238000006993 Weiss annulation reaction Methods 0.000 description 1
230000003187 abdominal effect Effects 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
206010000891 acute myocardial infarction Diseases 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
238000010171 animal model Methods 0.000 description 1
238000000889 atomisation Methods 0.000 description 1
230000006399 behavior Effects 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
230000002146 bilateral effect Effects 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
239000001110 calcium chloride Substances 0.000 description 1
235000011148 calcium chloride Nutrition 0.000 description 1
229910001628 calcium chloride Inorganic materials 0.000 description 1
238000004364 calculation method Methods 0.000 description 1
239000002775 capsule Substances 0.000 description 1
238000012754 cardiac puncture Methods 0.000 description 1
210000000748 cardiovascular system Anatomy 0.000 description 1
238000006555 catalytic reaction Methods 0.000 description 1
230000024245 cell differentiation Effects 0.000 description 1
229920002301 cellulose acetate Polymers 0.000 description 1
230000037020 contractile activity Effects 0.000 description 1
230000008828 contractile function Effects 0.000 description 1
235000021316 daily nutritional intake Nutrition 0.000 description 1
238000013480 data collection Methods 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
229910052805 deuterium Inorganic materials 0.000 description 1
208000033679 diabetic kidney disease Diseases 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
230000000857 drug effect Effects 0.000 description 1
238000001035 drying Methods 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
210000003191 femoral vein Anatomy 0.000 description 1
230000004153 glucose metabolism Effects 0.000 description 1
230000036541 health Effects 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
230000008935 histological improvement Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000009616 inductively coupled plasma Methods 0.000 description 1
238000001095 inductively coupled plasma mass spectrometry Methods 0.000 description 1
239000003983 inhalation anesthetic agent Substances 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
238000002642 intravenous therapy Methods 0.000 description 1
230000000302 ischemic effect Effects 0.000 description 1
230000002530 ischemic preconditioning effect Effects 0.000 description 1
208000037806 kidney injury Diseases 0.000 description 1
230000002045 lasting effect Effects 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
230000007774 longterm Effects 0.000 description 1
229910052943 magnesium sulfate Inorganic materials 0.000 description 1
235000019341 magnesium sulphate Nutrition 0.000 description 1
229910052748 manganese Inorganic materials 0.000 description 1
239000011572 manganese Substances 0.000 description 1
238000013460 mixed model approach Methods 0.000 description 1
229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
235000019796 monopotassium phosphate Nutrition 0.000 description 1
230000021332 multicellular organism growth Effects 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
239000006199 nebulizer Substances 0.000 description 1
210000000653 nervous system Anatomy 0.000 description 1
230000001019 normoglycemic effect Effects 0.000 description 1
230000001151 other effect Effects 0.000 description 1
230000036542 oxidative stress Effects 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
230000004962 physiological condition Effects 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
229920002223 polystyrene Polymers 0.000 description 1
GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
239000002243 precursor Substances 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
230000003449 preventive effect Effects 0.000 description 1
238000012545 processing Methods 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
210000003492 pulmonary vein Anatomy 0.000 description 1
238000005086 pumping Methods 0.000 description 1
238000011552 rat model Methods 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
239000012925 reference material Substances 0.000 description 1
230000009719 regenerative response Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
230000036387 respiratory rate Effects 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
210000004872 soft tissue Anatomy 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
239000012086 standard solution Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
229940036222 syprine Drugs 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
DSNBHJFQCNUKMA-SCKDECHMSA-N thromboxane A2 Chemical compound OC(=O)CCC\C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)O[C@@H]2O[C@H]1C2 DSNBHJFQCNUKMA-SCKDECHMSA-N 0.000 description 1
239000010936 titanium Substances 0.000 description 1
229910052719 titanium Inorganic materials 0.000 description 1
239000011573 trace mineral Substances 0.000 description 1
235000013619 trace mineral Nutrition 0.000 description 1
210000003437 trachea Anatomy 0.000 description 1
230000007704 transition Effects 0.000 description 1
229910001428 transition metal ion Inorganic materials 0.000 description 1
230000008733 trauma Effects 0.000 description 1
230000000472 traumatic effect Effects 0.000 description 1
231100000397 ulcer Toxicity 0.000 description 1
210000000626 ureter Anatomy 0.000 description 1
210000001631 vena cava inferior Anatomy 0.000 description 1
238000009423 ventilation Methods 0.000 description 1
238000005303 weighing Methods 0.000 description 1
239000012224 working solution Substances 0.000 description 1
230000037314 wound repair Effects 0.000 description 1

Landscapes

Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

ES11187394.9T 2002-03-08 2003-03-10 Prevención y/o tratamiento de la enfermedad cardiovascular y/o la insuficiencia cardíaca asociada Expired - Lifetime ES2642633T3 (es)

Applications Claiming Priority (6)

Application Number	Priority Date	Filing Date
NZ51772102		2002-03-08
NZ51772102		2002-03-08
NZ51772502		2002-03-11
NZ51772502		2002-03-11
US36438202P	2002-03-12	2002-03-12
US364382P		2002-03-12

Publications (1)

Publication Number	Publication Date
ES2642633T3 true ES2642633T3 (es)	2017-11-17

Family

ID=46801737

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ES11187394.9T Expired - Lifetime ES2642633T3 (es)	2002-03-08	2003-03-10	Prevención y/o tratamiento de la enfermedad cardiovascular y/o la insuficiencia cardíaca asociada

Country Status (3)

Country	Link
CA (2)	CA2828595C (fr)
ES (1)	ES2642633T3 (fr)
PT (2)	PT1487431E (fr)

2003
- 2003-03-10 CA CA2828595A patent/CA2828595C/fr not_active Expired - Fee Related
- 2003-03-10 ES ES11187394.9T patent/ES2642633T3/es not_active Expired - Lifetime
- 2003-03-10 CA CA2982327A patent/CA2982327A1/fr not_active Abandoned
- 2003-03-10 PT PT03744567T patent/PT1487431E/pt unknown
- 2003-03-10 PT PT111873949T patent/PT2500018T/pt unknown

Also Published As

Publication number	Publication date
CA2828595C (fr)	2017-11-28
PT2500018T (pt)	2017-10-04
CA2828595A1 (fr)	2003-09-25
CA2982327A1 (fr)	2003-09-25
PT1487431E (pt)	2012-08-02

Publication	Publication Date	Title
ES2386782T3 (es)	2012-08-30	Prevención y/o tratamiento de la enfermedad cardiovascular y/o la insuficiencia cardíaca asociada
Coppolino et al.	2018	Oxidative stress and kidney function: a brief update
Ohta	2011	Recent progress toward hydrogen medicine: potential of molecular hydrogen for preventive and therapeutic applications
US20030039697A1 (en)	2003-02-27	Matrices containing nitric oxide donors and reducing agents and their use
JP2019501965A (ja)	2019-01-24	一酸化窒素を含むガスを投与するための方法及び装置
US10052426B2 (en)	2018-08-21	Methods of administering nitric oxide to arterial or arterialized blood
WO2003057206A1 (fr)	2003-07-17	Solutions de cardioplegie au pyruvate a administrer au muscle cardiaque durant une operation chirurgicale avec circulation extracorporelle et procedes d'utilisation associes
Kim et al.	2011	A novel dithiol amide CB3 attenuates allergic airway disease through negative regulation of p38 mitogen-activated protein kinase
Albisser et al.	1977	9 the artificial pancreas
CN101164530B (zh)	2010-10-20	含稳定的丙酮酸钠的水溶液及其制法和用途
ES2642633T3 (es)	2017-11-17	Prevención y/o tratamiento de la enfermedad cardiovascular y/o la insuficiencia cardíaca asociada
JPWO2008133157A1 (ja)	2010-07-22	体温低下抑制剤
US11224633B2 (en)	2022-01-18	Kit for treating sepsis and/or any systemic (SIRS) or damaging cellular hyperinflammation
CA2180506C (fr)	2003-11-25	Monoxyde d'azote inhale pour la prevention et le traitement des reactions inflammatoires
Swenson	2004	Therapeutic hypercapnic acidosis: pushing the envelope
Eiselt et al.	2000	Oxidative stress: the effect of erythropoietin and the dialysis membrane
CA2655644A1 (fr)	2007-12-27	Solution et methode reduisant, traitant et/ou prevenant le stress oxydatif et l'activation cellulaire
Jurcău et al.	2023	Molecular hydrogen, a therapeutic gas with antioxidant effects, general aspects and mechanisms.
JP2021006262A (ja)	2021-01-21	透析装置、アクセプター薬剤、ドナー薬剤、リンス液およびリンス液としての使用方法
Kim et al.	2012	Effectiveness of antioxidant and membrane oxygenator in acute respiratory distress syndrome by endotoxin
Chan	2012	Basis of life
Tsukamoto et al.	2009	Fatal hyperkalemia due to rapid red cell transfusion in a critically ill patient
CN112168841A (zh)	2021-01-05	一种增加人一氧化氮生物利用度的方法
Badawy et al.	2022	Hyperchloremia in Critically Ill Patients in ICU
Diaz-Buxo	2007	Peritoneal dialysis solutions low in glucose degradation products: clinical experience and outcomes